


Product Data Sheet

Cas No.:	1373431-65-2	Cat. No:	PL08919
Product Name:	Talazoparib tosylate		
Product synonym:	-		
Chemical name:	Talazoparib tosylate		
MF:	C26H22F2N6O4S	FW:	552.552490711212
Purity:	≥99%	Batch No.:	-
Storage:			
Structural formula:			
λmax:	-	Formulation:	-
Solubility :			
SMILES :	S(C1C=CC(C)=CC=1)(=O)(=O)O.FC1C=C2C(NN=C3C2=C(C=1)N[C@H](C1C=CC(=CC=1)F)[C@H]3C1=NC=NN1C)=O		
InChI Code:	-		
InChI Key:			
WARNING This product is not for human or veterinary use.			

Product Description

Talazoparib tosylate (BMN 673ts) 是一种新型，高效，有可口服活性的 PARP1/2 抑制剂，抑制PARP1的IC₅₀ 值为 0.57 nM。

生物活性	Talazoparib tosylate (BMN 673ts) is a novel, potent and orally available PARP1/2 inhibitor with an IC ₅₀ of 0.57 nM for PARP1.
IC ₅₀ & Target[1][2]	IC ₅₀ : 0.57 nM (PARP1)
体外研究(In Vitro)	Talazoparib is a potent PARP1/2 inhibitor (PARP1 IC ₅₀ =0.57 nM), it has no effect on PARG activity at concentrations up to 1 μM. Talazoparib binds to PARP1 with a dissociation constant (K _D) of 0.29 nM. Talazoparib inhibits PARP1 and -2 to a similar extent, with K _i s of 1.20 and 0.85 nM, respectively. Talazoparib selectively targets tumor cells with BRCA1, BRCA2, or PTEN gene defects with 20- to more than 200-fold greater potency than existing PARP1/2 inhibitors. Talazoparib targets tumor cells with homologous recombination gene defects. Tumor models that are either BRCA1-deficient (MX-1 and SUM149) or BRCA2-deficient (Capan-1) are profoundly sensitive to Talazoparib. Talazoparib induces nuclear γ-H2AX foci at concentrations as low as 100 pM. has not independently confirmed the accuracy of

体内研究(In Vivo)	Talazoparib is readily orally bioavailable, with more than 40% absolute oral bioavailability in rats when dosed in carboxymethyl cellulose. Oral administration of Talazoparib elicits remarkable antitumor activity; xenografted tumors that carry defects in DNA repair due to BRCA mutations or PTEN deficiency are profoundly sensitive to oral Talazoparib treatment at well-tolerated doses in mice. Synergistic or additive antitumor effects are also found when Talazoparib is combined with temozolomide, SN38, or platinum drugs. has not independently confirmed the accuracy of these methods. They are for reference only.
包装储存	4°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶解度数据	In Vitro: DMSO : ≥ 108 mg/mL (195.46 mM)配制储备液